VITAMINVEIEN 4, OSLO, Q8
Reports First Quarter 2026 Results With Both Revenue and Adjusted EBITDA Exceeding High End of Guidance Ranges
Reports Fourth Quarter and Full-Year 2025 Results Ahead of Expectations, Announces $300 Million Share Repurchase Program
Fourth Quarter Revenue and Adjusted EBITDA Expected to Exceed Guidance; Full-Year Revenue Growth Surpasses 26%
Declares Upcoming Cash Dividend of $0.40 per Share Under Its Recurring Dividend Program
Voting Results of the 2025 Annual General Meeting
Annual General Meeting of Shareholders
Reports Third Quarter 2025 Results Ahead of Expectations, Raises Full-Year Guidance Ranges for Both Revenue and Adjusted EBITDA
Lin Song Becomes Sole CEO
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
S-8 POS
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload
Confidential Treatment Order
NT 20-F